Imperial Brands, Pfizer Inc. and Dr. Reddy Laboratories Ltd. are Dominating the Europe Smoking Cessation and Nicotine De-Addiction Market in 2028

Europe Smoking Cessation and Nicotine De-Addiction Market is expected to grow with the CAGR of 25.3% in the forecast period of 2021 to 2028. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/europe-smoking-cessation-and-nicotine-de-addictions-market

Europe smoking cessation and nicotine de-addiction market is a highly consolidated market, which includes specific number of key players as well as local players. The market has witnessed increased strategic developments owing to favourable market scenario.

The major players dealing in Europe smoking cessation and nicotine de-addiction market are introducing strong range of product portfolio. This helped companies to maximize the sales with enhanced product portfolio.

For instance,

  • In August 2019, British American Tobacco had announced that it had received approval from the South African Competition Commission to acquire Twisp, a leading South African vaping products company. Twisp is South Africa's biggest multi-chain vapour vending dealer. It is the number one choice for adult customers who try future lower-rises in South African countries and has approximately 70 dedicated outlets at prime regional sites, major supermarkets, and international e-commerce channels. This will help increase in revenue for British American Tobacco.
  • In December 2019, Cambrex Corporation had acquired Perima Funds company. The acquisition will support the company's ongoing growth of Cambrex's integrated services offering, which will enhance its ability of service to its global customer base and increase its capabilities to provide additional world class services to support the analysis. This will help rise in revenue for Cambrex Corporation.

Imperial Brands is dominating the market and the other players in the market are Cipla Inc., Johnson & Johnson Services, Inc., Takeda Consumer Healthcare Company Limited, Alkalon A/S, 22nd Century Group, Inc., GlaxoSmithKline plc., Imperial Brands, Japan Tobacco Inc., British American Tobacco, Perrigo Company plc, Fertin Pharma, Cambrex Corporation, Dr. Reddy’s Laboratories Ltd., Pfizer Inc. and Strides Pharma Science Limited among others.

Europe Smoking Cessation and Nicotine De-Addiction Market

Imperial Brands

Imperial Brands founded in 1901 headquartered in Bristol, U.K. as public ownership. The company is engaged in the manufacturing of providing fast moving consumer goods borne out of a strong tobacco. The company have product category which are new generation products. The company has wide global presence across the U.K., Germany, France, and U.S.

Pfizer Inc.

Pfizer Inc., founded in 1849 headquartered in New York, U.S.as public ownership. The company is engaged in the manufacturing of wide range of health care products including innovative medicines and vaccines. The company offers wide range of product categories such as Abrilada Injection, Accupril, Accuretic, Acetylcysteine, Adenosine, Aldactazide, and among many others under which the market focused category is Nicotrol Inhaler. The company has presence in a North America, South America, Europe, Asia-Pacific, Middle East and Africa.

For instance,

  • In March 2021, Pfizer Inc. announced an expansion in the business with the development of supplemental New Drug Application used to treat anaplastic lymphoma kinase. This will help raise revenue for Pfizer Inc.

Dr. Reddy Laboratories Ltd.

Dr. Reddy Laboratories Ltd. founded in 1984, is headquartered in Telangana, India as public ownership. The company is engaged in manufacturing and marketing the pharmaceutical products. The company has product category such as Habitrol and Habitrol is market focused segment. The company has wide global presence in Europe, Asia-Pacific, Americas and South Africa.

For instance,

  • In September 2019, Dr. Reddy Laboratories Ltd. launched hydrochloride extended-release tablets, a therapeutically equivalent generic version of Zyban, in the U.S. market. It will help the company to increase its customer base.